Immunological consequences of strain variation within the Mycobacterium tuberculosis complex

European Journal of Immunology

Volumn 47, Issue 3, 2017, Pages 432-445

  Tientcheu, Leopold D ^a,b   Koch, Anastasia ^c   Ndengane, Mthawelenga ^c   Andoseh, Genevieve ^b   Kampmann, Beate ^a,d   Wilkinson, Robert J ^c,d,e  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e THE FRANCIS CRICK INSTITUTE   (United Kingdom)

Author keywords

Adaptive and innate immunity; Genetic diversity; Host response; Mycobacterium tuberculosis complex; Translational implications

Indexed keywords

BCG VACCINE; EPITOPE; LECTIN; MANNOSE BINDING LECTIN; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; CELLULAR IMMUNITY; DENDRITIC CELL; GENETIC VARIABILITY; GENETIC VARIATION; GENOTYPING TECHNIQUE; HOST; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MACROPHAGE; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS COMPLEX; NEUTROPHIL; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; ANIMAL; ANTIGENIC VARIATION; GENETICS; GENOTYPE; IMMUNOLOGY; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PHYLOGENY; SPECIES DIFFERENCE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENIC VARIATION; GENETIC VARIATION; GENOTYPE; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; MYCOBACTERIUM TUBERCULOSIS; PHYLOGENY; SPECIES SPECIFICITY; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 85013651730     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201646562     Document Type: Review

References (123)

1. Brosch, R., Gordon, S. V., Marmiesse, M., Brodin, P., Buchrieser, C., Eiglmeier, K., Garnier, T. et al., A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc. Natl. Acad. Sci. U.S.A. 2002. 99: 3684–3689.
2. Brites, D. and Gagneux, S., Old and new selective pressures on Mycobacterium tuberculosis. Infect. Genet. Evol. 2012. 12: 678–685.
3. Clifton-Hadley, R. S., Wilesmith, J. W., Richards, M. S., Upton, P. and Johnston, S., The occurrence of Mycobacterium bovis infection in cattle in and around an area subject to extensive badger (Meles meles) control. Epidemiol. Infect. 1995. 114: 179–193.
4. Smith, N. H., Crawshaw, T., Parry, J. and Birtles, R. J., Mycobacterium microti: more diverse than previously thought. J. Clin. Microbiol. 2009. 47: 2551–2559.
5. Kiers, A., Klarenbeek, A., Mendelts, B., van Soolingen, D. and Koëter, G., Transmission of Mycobacterium pinnipedii to humans in a zoo with marine mammals. Int. J. Tuberc. Lung Dis. 2008. 12: 1469–1473.
6. Schoepf, K., Prodinger, W. M., Glawischnig, W., Hofer, E., Revilla-Fernandez, S., Hofrichter, J., Fritz, J. et al., A two-years' survey on the prevalence of tuberculosis caused by Mycobacterium caprae in Red Deer (Cervus elaphus) in the Tyrol, Austria. ISRN Vet Sci. 2012. 2012: 245138–7.
7. Gey van Pittius, N. C., van Helden, P. D. and Warren, R. M., Characterization of Mycobacterium orygis. Emerging Infect. Dis. 2012. 18: 1708–1709.
8. Alexander, K. A., Laver, P. N., Michel, A. L., Williams, M., van Helden, P. D., Warren, R. M. and Gey van Pittius, N. C., Novel Mycobacterium tuberculosis complex pathogen, M. mungi. Emerging Infect. Dis. 2010. 16: 1296–1299.
9. Gagneux, S., Deriemer, K., Van, T., Kato-Maeda, M., de Jong, B. C., Narayanan, S., Nicol, M. et al., Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 2006. 103: 2869–2873.
10. Comas, I., Chakravartti, J., Small, P. M., Galagan, J., Niemann, S., Kremer, K., Ernst, J. D. et al., Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat. Genet. 2010. 42: 498–503.
11. de Jong, B. C., Adetifa, I., Walther, B., Hill, P. C., Antonio, M., Ota, M. and Adegbola, R. A., Differences between tuberculosis cases infected with Mycobacterium africanum, West African type 2, relative to Euro-American Mycobacterium tuberculosis: an update. FEMS Immunol. Med. Microbiol. 2010. 58: 102–105.
12. Merker, M., Blin, C., Mona, S., Duforet-Frebourg, N., Lecher, S., Willery, E., Blum, M. G. B. et al., Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat. Genet. 2015. 47: 242–249.
13. Stucki, D., Brites, D., Jeljeli, L., Coscolla, M., Liu, Q., Trauner, A., Fenner, L. et al., Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages. Nat. Genet. 2016. 48: 1535–1543.
14. Mitchison, D. A., Wallace, J. G., Bhatia, A. L., Selkon, J. B., Subbaiah, T. V. and Lancaster, M. C., A comparison of the virulence in guinea-pigs of South Indian and British tubercle bacilli. Tubercle. 1960. 41: 1–22.
15. Nicol, M. P. and Wilkinson, R. J., The clinical consequences of strain diversity in Mycobacterium tuberculosis. Trans. R. Soc. Trop. Med. Hyg. 2008. 102: 955–965.
16. Valway, S. E., Sanchez, M. P., Shinnick, T. F., Orme, I., Agerton, T., Hoy, D., Jones, J. S. et al., An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N. Engl. J. Med. 1998. 338: 633–639.
17. Manca, C., Tsenova, L., Barry, C. E., Bergtold, A., Freeman, S., Haslett, P. A., Musser, J. M. et al., Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J. Immunol. 1999. 162: 6740–6746.
18. Manca, C., Tsenova, L., Bergtold, A., Freeman, S., Tovey, M., Musser, J. M., Barry, C. E. et al., Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta. Proc. Natl. Acad. Sci. U.S.A. 2001. 98: 5752–5757.
19. Tsenova, L., Ellison, E., Harbacheuski, R., Moreira, A. L., Kurepina, N., Reed, M. B., Mathema, B. et al., Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J. Infect. Dis. 2005. 192: 98–106.
20. Reed, M. B., Domenech, P., Manca, C., Su, H., Barczak, A. K., Kreiswirth, B. N., Kaplan, G. et al., A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 2004. 431: 84–87.
21. Click, E. S., Moonan, P. K., Winston, C. A., Cowan, L. S. and Oeltmann, J. E., Relationship between Mycobacterium tuberculosis phylogenetic lineage and clinical site of tuberculosis. Clin. Infect. Dis. 2012. 54: 211–219.
22. Thwaites, G., Caws, M., Chau, T. T. H., D'Sa, A., Lan, N. T. N., Huyen, M. N. T., Gagneux, S. et al., Relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis. J. Clin. Microbiol. 2008. 46: 1363–1368.
23. Coscolla, M. and Gagneux, S., Does M. tuberculosis genomic diversity explain disease diversity? Drug Discov. Today Dis. Mech. 2010. 7: e43–e59.
24. Stein, C. M., Genetic epidemiology of tuberculosis susceptibility: impact of study design. PLoS Pathog. 2011. 7: e1001189.
25. Stamm, C. E., Collins, A. C. and Shiloh, M. U., Sensing of Mycobacterium tuberculosis and consequences to both host and bacillus. Immunol. Rev. 2015. 264: 204–219.
26. O'Garra, A., Redford, P. S., McNab, F. W., Bloom, C. I., Wilkinson, R. J. and Berry, M. P. R., The immune response in tuberculosis. Annu. Rev. Immunol. 2013. 31: 475–527.
27. Kallenius, G., Correia-Neves, M., Buteme, H., Hamasur, B. and Svenson, S. B., Lipoarabinomannan, and its related glycolipids, induce divergent and opposing immune responses to Mycobacterium tuberculosis depending on structural diversity and experimental variations. Tuberculosis (Edinb). 2016. 96: 120–130.
28. Smet, M., Pollard, C., De Beuckelaer, A., Van Hoecke, L., Vander Beken, S., De Koker, S., Al Dulayymi, J. R. et al., Mycobacterium tuberculosis-associated synthetic mycolates differentially exert immune stimulatory adjuvant activity. Eur. J. Immunol. 2016. 46: 2149–2154.
29. Kleinnijenhuis, J., Oosting, M., Joosten, L. A. B., Netea, M. G. and van Crevel, R., Innate immune recognition of Mycobacterium tuberculosis. Clin. Dev. Immunol. 2011. 2011: 405310–405312.
30. Tailleux, L., Schwartz, O., Herrmann, J.-L., Pivert, E., Jackson, M., Amara, A., Legres, L. et al., DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J. Exp. Med. 2003. 197: 121–127.
31. Schlesinger, L. S., Kaufman, T. M., Iyer, S., Hull, S. R. and Marchiando, L. K., Differences in mannose receptor-mediated uptake of lipoarabinomannan from virulent and attenuated strains of Mycobacterium tuberculosis by human macrophages. J. Immunol. 1996. 157: 4568–4575.
32. Torrelles, J. B., Knaup, R., Kolareth, A., Slepushkina, T., Kaufman, T. M., Kang, P., Hill, P. J. et al., Identification of Mycobacterium tuberculosis clinical isolates with altered phagocytosis by human macrophages due to a truncated lipoarabinomannan. J. Biol. Chem. 2008. 283: 31417–31428.
33. Carmona, J., Cruz, A., Moreira-Teixeira, L., Sousa, C., Sousa, J., Osório, N. S., Saraiva, A. L. et al., Mycobacterium tuberculosis strains are differentially recognized by TLRs with an impact on the immune response. PLOS ONE 2013. 8: e67277.
34. van Crevel, R., Ottenhoff, T. H. M. and van der Meer, J. W. M., Innate immunity to Mycobacterium tuberculosis. Clin. Microbiol. Rev. 2002. 15: 294–309.
35. Rocha-Ramírez, L. M., Estrada-García, I., López-Marín, L. M., Segura-Salinas, E., Méndez-Aragón, P., van Soolingen, D., Torres-González, R. et al., Mycobacterium tuberculosis lipids regulate cytokines, TLR-2/4 and MHC class II expression in human macrophages. Tuberculosis 2008. 88: 212–220.
36. Gopal, R., Monin, L., Slight, S., Uche, U., Blanchard, E., Fallert Junecko, B. A., Ramos-Payan, R. et al., Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog. 2014. 10: e1004099.
37. Caws, M., Thwaites, G., Dunstan, S., Hawn, T. R., Lan, N. T. N., Thuong, N. T. T., Stepniewska, K. et al., The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog. 2008. 4: e1000034.
38. Ghiran, I., Barbashov, S. F., Klickstein, L. B., Tas, S. W., Jensenius, J. C. and Nicholson-Weller, A., Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J. Exp. Med. 2000. 192: 1797–1808.
39. Bonar, A., Chmiela, M., Rudnicka, W. and Rózalska, B., Mannose-binding lectin enhances the attachment and phagocytosis of mycobacteria in vitro. Arch. Immunol. Ther. Exp. (Warsz.). 2005. 53: 437–441.
40. Ezekowitz, R. A., Role of the mannose-binding lectin in innate immunity. J. Infect. Dis. 2003. 187(Suppl 2): S335–S339.
41. Singla, N., Gupta, D., Joshi, A., Batra, N., Singh, J. and Birbian, N., Association of mannose-binding lectin gene polymorphism with tuberculosis susceptibility and sputum conversion time. Int. J. Immunogenet. 2012. 39: 10–14.
42. Thye, T., Niemann, S., Walter, K., Homolka, S., Intemann, C. D., Chinbuah, M. A., Enimil, A. et al., Variant G57E of mannose binding lectin associated with protection against tuberculosis caused by Mycobacterium africanum but not by M. tuberculosis. PLOS ONE 2011. 6: e20908.
43. Eisen, D. P. and Minchinton, R. M., Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin. Infect. Dis. 2003. 37: 1496–1505.
44. Azad, A. K., Sadee, W. and Schlesinger, L. S., Innate immune gene polymorphisms in tuberculosis. Infect. Immun. 2012. 80: 3343–3359.
45. Scriba, T. J., Coussens, A. K. and Fletcher, H. A., Human immunology of tuberculosis. Microbiol Spectr. 2016. 4.
46. Theus, S. A., Cave, M. D., Eisenach, K., Walrath, J., Lee, H., Mackay, W., Whalen, C. et al., Differences in the growth of paired Ugandan isolates of Mycobacterium tuberculosis within human mononuclear phagocytes correlate with epidemiological evidence of strain virulence. Infect. Immun. 2006. 74: 6865–6876.
47. Portevin, D., Gagneux, S., Comas, I. and Young, D., Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages. PLoS Pathog. 2011. 7: e1001307.
48. Ribeiro, S. C. M., Gomes, L. L., Amaral, E. P., Andrade, M. R. M., Almeida, F. M., Rezende, A. L., Lanes, V. R. et al., Mycobacterium tuberculosis strains of the modern sublineage of the Beijing family are more likely to display increased virulence than strains of the ancient sublineage. J. Clin. Microbiol. 2014. 52: 2615–2624.
49. Homolka, S., Niemann, S., Russell, D. G. and Rohde, K. H., Functional genetic diversity among Mycobacterium tuberculosis complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes during intracellular survival. PLoS Pathog. 2010. 6: e1000988.
50. Sarkar, R., Lenders, L., Wilkinson, K. A., Wilkinson, R. J. and Nicol, M. P., Modern lineages of Mycobacterium tuberculosis exhibit lineage-specific patterns of growth and cytokine induction in human monocyte-derived macrophages. PLOS ONE 2012. 7: e43170.
51. Manca, C., Reed, M. B., Freeman, S., Mathema, B., Kreiswirth, B., Barry, C. E. and Kaplan, G., Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infect. Immun. 2004. 72: 5511–5514.
52. Newton, S. M., Smith, R. J., Wilkinson, K. A., Nicol, M. P., Garton, N. J., Staples, K. J., Stewart, G. R. et al., A deletion defining a common Asian lineage of Mycobacterium tuberculosis associates with immune subversion. Proc. Natl. Acad. Sci. U.S.A. 2006. 103: 15594–15598.
53. Eum, S. Y., Kong, J.-H., Hong, M.-S., Lee, Y.-J., Kim, J. H., Hwang, S.-H., Cho, S.-N. et al., Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 2010. 137: 122–128.
54. Berry, M. P. R., Graham, C. M., McNab, F. W., Xu, Z., Bloch, S. A. A., Oni, T., Wilkinson, K. A. et al., An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010. 466: 973–977.
55. Martineau, A. R., Newton, S. M., Wilkinson, K. A., Kampmann, B., Hall, B. M., Nawroly, N., Packe, G. E. et al., Neutrophil-mediated innate immune resistance to mycobacteria. J. Clin. Invest. 2007. 117: 1988–1994.
56. Kisich, K. O., Higgins, M., Diamond, G. and Heifets, L., Tumor necrosis factor alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils. Infect. Immun. 2002. 70: 4591–4599.
57. Romero, M. M., Basile, J. I., Lopez, B., Ritacco, V., Barrera, L., Sasiain, M. D. C. and Alemán, M., Outbreaks of Mycobacterium tuberculosis MDR strains differentially induce neutrophil respiratory burst involving lipid rafts, p38 MAPK and Syk. BMC Infect. Dis. 2014. 14: 262.
58. Romero, M. M., Balboa, L., Basile, J. I., Lopez, B., Ritacco, V., la Barrera de, S. S., Sasiain, M. C. et al., Clinical isolates of Mycobacterium tuberculosis differ in their ability to induce respiratory burst and apoptosis in neutrophils as a possible mechanism of immune escape. Clin. Dev. Immunol. 2012. 2012: 152546–11.
59. Reyes-Martínez, J. E., Nieto-Patlán, E., Nieto-Patlán, A., Gonzaga-Bernachi, J., Santos-Mendoza, T., Serafín-López, J., Chávez-Blanco, A. et al., Differential activation of dendritic cells by Mycobacterium tuberculosis Beijing genotype. Immunol. Invest. 2014. 43: 436–446.
60. Rajashree, P., Supriya, P. and Das, S. D., Differential migration of human monocyte-derived dendritic cells after infection with prevalent clinical strains of Mycobacterium tuberculosis. Immunobiology 2008. 213: 567–575.
61. Wang, C., Peyron, P., Mestre, O., Kaplan, G., van Soolingen, D., Gao, Q., Gicquel, B. et al., Innate immune response to Mycobacterium tuberculosis Beijing and other genotypes. PLOS ONE 2010. 5: e13594.
62. Krishnan, N., Malaga, W., Constant, P., Caws, M., Tran, T. H. C., Salmons, J., Nguyen, T. N. L. et al., Mycobacterium tuberculosis lineage influences innate immune response and virulence and is associated with distinct cell envelope lipid profiles. PLOS ONE 2011. 6: e23870.
63. Kaufmann, S. H., How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 2001. 1: 20–30.
64. Canaday, D. H., Wilkinson, R. J., Li, Q., Harding, C. V., Silver, R. F. and Boom, W. H., CD4(+) and CD8(+) T cells kill intracellular Mycobacterium tuberculosis by a perforin and Fas/Fas ligand-independent mechanism. J. Immunol. 2001. 167: 2734–2742.
65. Tientcheu, L. D., Sutherland, J. S., de Jong, B. C., Kampmann, B., Jafali, J., Adetifa, I. M., Antonio, M. et al., Differences in T-cell responses between Mycobacterium tuberculosis and Mycobacterium africanum-infected patients. Eur. J. Immunol. 2014. 44: 1387–1398.
66. Zimmermann, N., Thormann, V., Hu, B., Köhler, A.-B., Imai-Matsushima, A., Locht, C., Arnett, E. et al., Human isotype-dependent inhibitory antibody responses against Mycobacterium tuberculosis. EMBO Mol. Med. 2016: e201606330.
67. Lu, L. L., Chung, A. W., Rosebrock, T. R., Ghebremichael, M., Yu, W. H., Grace, P. S., Schoen, M. K. et al., A functional role for antibodies in Tuberculosis. Cell. 2016. 167: 433–443.e14.
68. Kato-Maeda, M., Shanley, C. A., Ackart, D., Jarlsberg, L. G., Shang, S., Obregon-Henao, A., Harton, M. et al., Beijing sublineages of Mycobacterium tuberculosis differ in pathogenicity in the guinea pig. Clin. Vaccine Immunol. 2012. 19: 1227–1237.
69. Kim, W. S., Kim, J.-S., Cha, S. B., Han, S. J., Kim, H., Kwon, K. W., Kim, S. J. et al., Virulence-Dependent alterations in the kinetics of immune cells during pulmonary infection by Mycobacterium tuberculosis. PLOS ONE 2015. 10: e0145234.
70. Ordway, D., Henao-Tamayo, M., Harton, M., Palanisamy, G., Troudt, J., Shanley, C., Basaraba, R. J. et al., The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J. Immunol. 2007. 179: 522–531.
71. Copin, R., Coscollá, M., Seiffert, S. N. and Bothamley, G., Sequence diversity in the pe_pgrs genes of Mycobacterium tuberculosis is independent of human T cell recognition. MBio. 2014. 5: e00960-13.
72. Bryant, J. M., Harris, S. R., Parkhill, J., Dawson, R., Diacon, A. H., van Helden, P., Pym, A. et al., Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Lancet Respir. Med. 2013. 1: 786–792.
73. Sampson, S. L., Mycobacterial PE/PPE proteins at the host-pathogen interface. Clin. Dev. Immunol. 2011. 2011: 497203–497211.
74. Vordermeier, H. M., Hewinson, R. G., Wilkinson, R. J., Wilkinson, K. A., Gideon, H. P., Young, D. B. and Sampson, S. L., Conserved immune recognition hierarchy of mycobacterial PE/PPE proteins during infection in natural hosts. PLOS ONE 2012. 7: e40890.
75. Coscolla, M., Copin, R., Sutherland, J., Gehre, F., de Jong, B., Owolabi, O., Mbayo, G. et al., M. tuberculosis T Cell epitope analysis reveals paucity of antigenic variation and identifies rare variable TB antigens. Cell Host & Microbe. 2015. 18: 538–548.
76. Parwati, I., van Crevel, R. and van Soolingen, D., Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. The Lancet Infect. Dis. 2010. 10: 103–111.
77. Abebe, F. and Bjune, G., The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guérin (BCG) vaccines: is there a link? Clin. Exp. Immunol. 2006. 145: 389–397.
78. López, B., Aguilar, D., Orozco, H., Burger, M., Espitia, C., Ritacco, V., Barrera, L. et al., A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin. Exp. Immunol. 2003. 133: 30–37.
79. Tsenova, L., Harbacheuski, R., Sung, N., Ellison, E., Fallows, D. and Kaplan, G., BCG vaccination confers poor protection against M. tuberculosis HN878-induced central nervous system disease. Vaccine. 2007. 25: 5126–5132.
80. Jeon, B. Y., Derrick, S. C., Lim, J., Kolibab, K., Dheenadhayalan, V., Yang, A. L., Kreiswirth, B. et al., Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice. Infect. Immun. 2008. 76: 5173–5180.
81. Henao-Tamayo, M., Shanley, C. A., Verma, D., Zilavy, A., Stapleton, M. C., Furney, S. K., Podell, B. et al., The efficacy of the BCG vaccine against newly emerging clinical strains of Mycobacterium tuberculosis. PLOS ONE 2015. 10: e0136500.
82. Grode, L., Seiler, P., Baumann, S., Hess, J., Brinkmann, V., Nasser Eddine, A., Mann, P. et al., Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J. Clin. Invest. 2005. 115: 2472–2479.
83. Fletcher, H. A. and Schrager, L., TB vaccine development and the End TB Strategy: importance and current status. Trans. R. Soc. Trop. Med. Hyg. 2016. 110: 212–218.
84. Coscolla, M. and Gagneux, S., Consequences of genomic diversity in Mycobacterium tuberculosis. Semin. Immunol. 2014. 26: 431–444.
85. Gillard, P., Yang, P.-C., Danilovits, M., Su, W.-J., Cheng, S.-L., Pehme, L., Bollaerts, A. et al., Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: a phase II randomised study. Tuberculosis (Edinb). 2016. 100: 118–127.
86. Homolka, S., Ubben, T. and Niemann, S., High sequence variability of the ppE18 gene of clinical Mycobacterium tuberculosis complex strains potentially impacts effectivity of vaccine candidate M72/AS01E. PLOS ONE 2016. 11: e0152200.
87. Hebert, A. M., Talarico, S., Yang, D., Durmaz, R., Marrs, C. F., Zhang, L., Foxman, B. et al., DNA polymorphisms in the pepA and PPE18 genes among clinical strains of Mycobacterium tuberculosis: implications for vaccine efficacy. Infect. Immun. 2007. 75: 5798–5805.
88. Anderson, S. T., Williams, A. J., Brown, J. R., Newton, S. M., Simsova, M., Nicol, M. P., Sebo, P. et al., Transmission of Mycobacterium tuberculosis undetected by tuberculin skin testing. Am. J. Respir. Crit. Care Med. 2006. 173: 1038–1042.
89. Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A. et al., Tuberculosis. Nat. Rev. Dis. Primers. 2016. 2: 16076.
90. de Jong, B. C., Hill, P. C., Brookes, R. H., Gagneux, S., Jeffries, D. J., Otu, J. K., Donkor, S. A. et al., Mycobacterium africanum elicits an attenuated T cell response to early secreted antigenic target, 6 kDa, in patients with tuberculosis and their household contacts. J. Infect. Dis. 2006. 193: 1279–1286.
91. Adekambi, T., Ibegbu, C. C., Cagle, S., Kalokhe, A. S., Wang, Y. F., Hu, Y., Day, C. L. et al., Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. J. Clin. Invest. 2015. 125: 3723–3723.
92. Riou, C., Perez Peixoto, B., Roberts, L., Ronacher, K., Walzl, G., Manca, C., Rustomjee, R. et al., Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis. PLOS ONE 2012. 7: e36886.
93. Tientcheu, L. D., Haks, M. C., Agbla, S. C., Sutherland, J. S., Adetifa, I. M., Donkor, S., Quinten, E. et al., Host immune responses differ between M. africanum- and M. tuberculosis-infected patients following standard anti-tuberculosis treatment. PLoS Negl. Trop. Dis. 2016. 10: e0004701.
94. Zumla, A., Maeurer, M., Host-Directed Therapies Network, Chakaya, J., Hoelscher, M., Ntoumi, F., Rustomjee, R. et al., Towards host-directed therapies for tuberculosis. Nat. Rev. Drug Discov. 2015. 14: 511–512.
95. Mayer-Barber, K. D., Andrade, B. B., Oland, S. D., Amaral, E. P., Barber, D. L., Gonzales, J., Derrick, S. C. et al., Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014. 511: 99–103.
96. Herb, F., Thye, T., Niemann, S., Browne, E. N. L., Chinbuah, M. A., Gyapong, J., Osei, I. et al., ALOX5 variants associated with susceptibility to human pulmonary tuberculosis. Hum. Mol. Genet. 2008. 17: 1052–1060.
97. Manca, C., Tsenova, L., Freeman, S., Barczak, A. K., Tovey, M., Murray, P. J., Barry, C. et al., Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J. Interferon Cytokine Res. 2005. 25: 694–701.
98. Guerra-Assunção, J. A., Crampin, A. C., Houben, R. M. G. J., Mzembe, T., Mallard, K., Coll, F., Khan, P. et al., Large-scale whole genome sequencing of M. tuberculosis provides insights into transmission in a high prevalence area. eLife Sciences 2015. 4: 110.
99. Middelkoop, K., Bekker, L.-G., Mathema, B., Shashkina, E., Kurepina, N., Whitelaw, A., Fallows, D. et al., Molecular epidemiology of Mycobacterium tuberculosis in a South African community with high HIV prevalence. J. Infect. Dis. 2009. 200: 1207–1211.
100. Eldholm, V., Rieux, A., Monteserin, J., Lopez, J. M., Palmero, D., Lopez, B., Ritacco, V. et al., Impact of HIV co-infection on the evolution and transmission of multidrug-resistant tuberculosis. eLife Sciences 2016. 5: 306.
101. Ranjbar, S., Boshoff, H. I., Mulder, A., Siddiqi, N., Rubin, E. J. and Goldfeld, A. E., HIV-1 replication is differentially regulated by distinct clinical strains of Mycobacterium tuberculosis. PLOS ONE 2009. 4: e6116.
102. Ranjbar, S., asenosky, L. D., Chow, N. and Goldfeld, A. E., Regulation of Mycobacterium tuberculosis-dependent HIV-1 transcription reveals a new role for NFAT5 in the toll-like receptor pathway. PLoS Pathog 2012. 8: e1002620.
103. Chen, R. Y., Dodd, L. E., Lee, M., Paripati, P., Hammoud, D. A., Mountz, J. M., Jeon, D. et al., PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci. Transl. Med. 2014. 6: 265ra166–265ra166.
104. Domenech, P., Rog, A., Moolji, J.-U.-D., Radomski, N., Fallow, A., Leon-Solis, L., Bowes, J. et al., Origins of a 350-kilobase genomic duplication in Mycobacterium tuberculosis and its impact on virulence. Infect. Immun. 2014. 82: 2902–2912.
105. Rhoads, A. and Au, K. F., PacBio sequencing and its applications. Genomics Proteomics Bioinformatics 2015. 13: 278–289.
106. Nicol, M. P., Sola, C., February, B., Rastogi, N., Steyn, L. and Wilkinson, R. J., Distribution of strain families of Mycobacterium tuberculosis causing pulmonary and extrapulmonary disease in hospitalized children in Cape Town, South Africa. J. Clin. Microbiol. 2005. 43: 5779–5781.
107. Cowley, D., Govender, D., February, B., Wolfe, M., Steyn, L., Evans, J., Wilkinson, R. J. et al., Recent and rapid emergence of W-Beijing strains of Mycobacterium tuberculosis in Cape Town, South Africa. Clin. Infect. Dis. 2008. 47: 1252–1259.
108. Wampande, E. M., Mupere, E., Jaganath, D., Nsereko, M., Mayanja, H. K., Eisenach, K., Boom, W. H. et al., Distribution and transmission of Mycobacterium tuberculosis complex lineages among children in peri-urban Kampala, Uganda. BMC Pediatr. 2015. 15: 140.
109. Jones, C., Whittaker, E., Bamford, A. and Kampmann, B., Immunology and pathogenesis of childhood TB. Paediatr. Respir. Rev. 2011. 12: 3–8.
110. Warner, D. F., Koch, A. and Mizrahi, V., Diversity and disease pathogenesis in Mycobacterium tuberculosis. Trends Microbiol. 2015. 23: 14–21.
111. Galagan, J. E., Genomic insights into tuberculosis. Nat. Rev. Genet. 2014. 15: 307–320.
112. Hershberg, R., Lipatov, M., Small, P. M., Sheffer, H., Niemann, S., Homolka, S., Roach, J. C. et al., High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLOS Biol. 2008. 6: e311.
113. Comas, I., Homolka, S., Niemann, S. and Gagneux, S., Genotyping of genetically monomorphic bacteria: DNA sequencing in Mycobacterium tuberculosis highlights the limitations of current methodologies. PLOS ONE 2009. 4: e7815.
114. Kato-Maeda, M., Metcalfe, J. Z. and Flores, L., Genotyping of Mycobacterium tuberculosis: application in epidemiologic studies. Future Microbiol. 2011. 6: 203–216.
115. Loman, N. J. and Pallen, M. J., Twenty years of bacterial genome sequencing. Nat. Rev. Microbiol. 2015. 13: 787–794.
116. Intemann, C. D., Thye, T., Niemann, S., Browne, E. N. L., Amanua Chinbuah, M., Enimil, A., Gyapong, J. et al., Autophagy gene variant IRGM -261T contributes to protection from tuberculosis caused by Mycobacterium tuberculosis but not by M. africanum strains. PLoS Pathog. 2009. 5: e1000577.
117. Intemann, C. D., Thye, T., Förster, B., Owusu-Dabo, E., Gyapong, J., Horstmann, R. D. and Meyer, C. G., MCP1 haplotypes associated with protection from pulmonary tuberculosis. BMC Genet. 2011. 12: 34.
118. Thye, T., Nejentsev, S., Intemann, C. D., Browne, E. N., Chinbuah, M. A., Gyapong, J., Osei, I. et al., MCP-1 promoter variant -362C associated with protection from pulmonary tuberculosis in Ghana, West Africa. Hum. Mol. Genet. 2009. 18: 381–388.
119. White, M. J., Tacconelli, A., Chen, J. S., Wejse, C., Hill, P. C., Gomes, V. F., Velez-Edwards, D. R. et al., Epiregulin (EREG) and human V-ATPase (TCIRG1): genetic variation, ethnicity and pulmonary tuberculosis susceptibility in Guinea-Bissau and The Gambia. Genes Immun. 2014. 15: 370–377.
120. Salie, M., an der Merwe, L., Möller, M., Daya, M., van der Spuy, G. D., van Helden, P. D., Martin, M. P. et al., Associations between human leukocyte antigen class I variants and the Mycobacterium tuberculosis subtypes causing disease. J. Infect. Dis. 2014. 209: 216–223.
121. Thuong, N. T. T., Tram, T. T. B., Dinh, T. D., Thai, P. V. K., Heemskerk, D., Bang, N. D., Chau, T. T. H. et al., MARCO variants are associated with phagocytosis, pulmonary tuberculosis susceptibility and Beijing lineage. Genes Immun. 2016. 17: 419–425.
122. van Crevel, R., Parwati, I., Sahiratmadja, E., Marzuki, S., Ottenhoff, T. H. M., Netea, M. G., van der Ven, A. et al., Infection with Mycobacterium tuberculosis Beijing genotype strains is associated with polymorphisms in SLC11A1/NRAMP1 in Indonesian patients with tuberculosis. J Infect Dis. 2009. 200: 1671–1674.
123. Ogarkov, O., Mokrousov, I., Sinkov, V., Zhdanova, S., Antipina, S. and Savilov, E., ‘Lethal’ combination of Mycobacterium tuberculosis Beijing genotype and human CD209 -336G allele in Russian male population. Infect. Genet. Evol. 2012. 12: 732–736.